The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Alzheimer’s and Parkinson’s diseases are the most prevalent neurodegenerative disorders. Their etiologies are idiopathic, and treatments are symptomatic and orientated towards cognitive or motor deficits. Neuropathologically, both are proteinopathies with pathological aggregates (plaques of amyloid-β peptide and neurofibrillary tangles of tau protein in Alzheimer’s disease, and Lewy bodies mostly composed of α-synuclein in Parkinson’s disease). These deposits appear in the nervous system in a predictable and accumulative sequence with six neuropathological stages. Both disorders present a long prodromal period, characterized by preclinical signs including hyposmia. Interestingly, the olfactory system, particularly the anterior olfactory nucleus, is initially and preferentially affected by the pathology. Cerebral atrophy revealed by magnetic resonance imaging must be complemented by histological analyses to ascertain whether neuronal and/or glial loss or neuropil remodeling are responsible for volumetric changes. It has been proposed that these proteinopathies could act in a prion-like manner in which a misfolded protein would be able to force native proteins into pathogenic folding (seeding), which then propagates through neurons and glia (spreading). Existing data have been examined to establish why some neuronal populations are vulnerable while others are resistant to pathology and to what extent glia prevent and/or facilitate proteinopathy spreading. Connectomic approaches reveal a number of hubs in the olfactory system (anterior olfactory nucleus, olfactory entorhinal cortex and cortical amygdala) that are key interconnectors with the main hubs (the entorhinal–hippocampal–cortical and amygdala–dorsal motor vagal nucleus) of network dysfunction in Alzheimer’s and Parkinson’s diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
The Human Connectome: A Structural Description of the Human Brain
Sporns, O., Tononi, G., & Kötter, R. (2005) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0010042 · Cited by 3,260 · cited 1×
“The term connectome, first used more than one decade ago [192], aims to describe the structural and functional connectivity of the human brain among connected (nodes) and highly connected (hubs) regions from an -omic perspective and to explore similarities and differences across disorders, including disconnectivity [7…”
BackgroundBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 2×
“There was a paradigmatic change in the approach to neurodegenerative diseases after the proposal of neuropathological staging in Alzheimer’s [49, 88] and Parkinson’s [57, 175] diseases.”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Cited by
Aging-associated sensory decline and Alzheimer’s disease
Hong, S., Baek, S.-H., Lai, M. K. P., Arumugam, T. V., & Jo, D.-G. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00776-y · Cited by 76
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Human amygdala involvement in Alzheimer's disease revealed by stereological and dia‐PASEF analysis
Gonzalez‐Rodriguez, M., Villar‐Conde, S., Astillero‐Lopez, V., Villanueva‐Anguita, P., Ubeda‐Banon, I., Flores‐Cuadrado, A., Martinez‐Marcos, A., & Saiz‐Sanchez, D. (2023) · Brain Pathology · doi:10.1111/bpa.13180 · Cited by 36
“Amygdala atrophy has been described in early stages of the disease [13], and it could be related to certain preclinical symptoms, such as olfactory deficits [14, 15] and/or emotional dysfunctions [16–18].”
BackgroundSelf-citation
Metadata
- Authors
- Ubeda-Bañon, I., Saiz-Sanchez, D., Flores-Cuadrado, A., Rioja-Corroto, E., Gonzalez-Rodriguez, M., Villar-Conde, S., Astillero-Lopez, V., Cabello-de la Rosa, J. P., Gallardo-Alcañiz, M. J., Vaamonde-Gamo, J., Relea-Calatayud, F., Gonzalez-Lopez, L., Mohedano-Moriano, A., Rabano, A., & Martinez-Marcos, A.
- Venue
- Translational Neurodegeneration
- Published
- 2020-06-03
- Volume
- 9
- Issue
- 1
- Pages
- 22-22
- ISSN
- 2047-9158 (ISSN-L)
- OpenAlex
- W3032289835
- Cited by
- 123
- References
- 47
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases. https://app.cochat.ai/papers/10.1186/s40035-020-00200-7
- The paper
- Ubeda-Bañon, I., Saiz-Sanchez, D., Flores-Cuadrado, A., Rioja-Corroto, E., Gonzalez-Rodriguez, M., Villar-Conde, S., Astillero-Lopez, V., Cabello-de la Rosa, J. P., Gallardo-Alcañiz, M. J., Vaamonde-Gamo, J., Relea-Calatayud, F., Gonzalez-Lopez, L., Mohedano-Moriano, A., Rabano, A., & Martinez-Marcos, A. (2020). The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases. Translational Neurodegeneration. https://doi.org/10.1186/s40035-020-00200-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.